What’s moving the Cogstate (ASX:CGS) share price today?

The Cogstate share price has been wobbly today after the company announced its sales for the quarter ending December 2020.

| More on:
Artificial Intelligence

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cogstate Limited (ASX: CGS) share price has been fluctuating today after the company released a business update to the ASX.

Earlier today the Cogstate share price was trading 2.33% higher but has now dipped into the red and is down by 0.47% to $1.07 per share.

About Cogstate 

Cogstate is a neuroscience technology company aiming to optimise brain health assessments. As such the company provides services to measure cognition and optimise the assessment of brain health to aid in new medicine development and provide earlier clinical insights. 

What did Cogstate announce?

This morning, ASX healthcare company Cogstate released its quarterly sales update. The company reported that its clinical trials sales contracts executed during the last quarter of 2020 amounted to US$14.3 million.

That result takes the total value of sales during the first half of FY21 to US$22.6 million, which is down from US$26.9 million the prior corresponding period. The company noted that the global pandemic has resulted in sales delays for the company.

In the healthcare segment of the business, Cogstate also announced that it has received a payment from Japanese pharmaceutical giant Eisai. The payment is part of a global license agreement, in which Eisai has agreed to pay Cogstate an upfront royalty of US$15 million to exclusively distribute its digital cognitive technologies. In addition, the agreement provides for cumulative royalties of at least US$30 million over the term of the license, unless terminated earlier.

Management commentary

The strong half year result follows the record US$46.0 million of sales contracts executed in FY20.

Cogstate CEO Brad O’Connor welcomed the news, saying:

In the context of the global pandemic and the various stay-at-home orders in place around the world, which have certainly made trial recruitment and participation more difficult than normal, the clinical trials sales result is very pleasing. This result demonstrates that the level of demand from pharmaceutical companies for Cogstate technology and services that was evident during FY20 has continued into FY21, notwithstanding the challenging external environment.

The company also noted that its recent deal signed with Eisai has not been included in the quarterly or half yearly results.

The Cogstate share price is trading 194% higher than this time last year, and on current prices the company has a market capitalisation of $182 million.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Top ten gold trophy.
Share Market News

Here are the top 10 ASX 200 shares today

These ASX 200 shares ended the week on a high.

Read more »

a shiba inu dog looks happily at eh camera with his tongue out while his owner hods him on his chest as he sleeps on a hammock.

Here’s why the Dogecoin price has had such a great week

Economic data out of the United States and a surprise announcement by BlackRock offered some healthy tailwinds to cryptos over…

Read more »

A pair of legs can bee seen on the floor buried under a pile of paperwork, indicating a high volume day
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Friday

Our most traded ASX 200 share today has lost more than 10%. Ouch.

Read more »

A futuristic view of electric vehicle technology with speeding bright light trails indicating power.
Resources Shares

New records and looming deficits. Why ASX lithium stocks are in the spotlight

Demand for lithium is booming alongside rocketing growth in EV production, sending the price of the battery critical metal up…

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Share Market News

Is the Telstra share price a buy after the telco’s FY22 results?

Is the Telstra share price good value now?

Read more »

A male ASX 200 broker wearing a blue shirt and black tie holds one hand to his chin with the other arm crossed across his body as he watches stock prices on a digital screen while deep in thought
Share Market News

5 things to watch on the ASX 200 on Friday

Here's what to expect on the ASX 200 on Friday...

Read more »

Blue light arrows pointing up, indicating a strong rising share price
Share Market News

Here are the top 10 ASX 200 shares today

These ASX 200 shares bested the rest on Thursday.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Thursday

Our most traded ASX 200 share of the day was at one stage up 19%...

Read more »